Showing 761-770 of 2378 results for "".
Bruton Tyrosine Kinase Inhibition in Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/bruton-tyrosine-kinase-inhibition-in-multiple-sclerosis/31872/The missing link for treatment optimization?Teleneurology for Primary Headache Disorders
https://practicalneurology.com/diseases-diagnoses/headache-pain/teleneurology-for-primary-headache-disorders/31669/During the COVID-19 public health emergency, remote and in-person care for headache disorders is necessary to reduce patient risk.- Epilepsy Essentialshttps://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/PN1005epilepsy-pdf/31388/Exploring the Complex Interplay Between Epilepsy and Mood DisordersEpilepsy and depression frequently coexist as comorbid conditions, significantly impacting patients' quality of life. Comorbidity, defined as the simultaneous occurrence of two or more diseases, does not necessarily indicate causalit
- Movement Disorders Focushttps://practicalneurology.com/diseases-diagnoses/movement-disorders/pn0607-movementdisorder-pdf/31164/Sydenham’s Chorea in Adolescents: Clinical Presentation and ManagementSydenham’s chorea is a critical movement disorder in adolescents, often emerging as a delayed neurological complication of acute rheumatic fever (ARF) following a Group A streptococcal infection. While clinicians might first consi
- Business Advisorhttps://practicalneurology.com/columns/practice-management/business-advisor/31385/Optimizing Neurology Practice Management: Insights from Parkinson’s LawNeurology practitioners possess extensive knowledge of neurological disorders such as Parkinson’s disease, yet many remain unaware of Parkinson’s Law, a concept introduced by sociologist C. Northcote Parkinson in the 1950s. Parki
Case Report: Cyclophosphamide as Rescue Agent in Myasthenic Crisis
https://practicalneurology.com/diseases-diagnoses/neuromuscular/case-report-cyclophosphamide-as-rescue-agent-in-myasthenic-crisis/30120/When patients are refractory to first-line treatments for myasthenic crisis, cyclophosphamide may have benefits and warrants further study.Neuropsychiatric Aspects of Alzheimer’s Disease
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/neuropsychiatric-aspects-of-alzheimers-disease/31538/Clinically significant neuropsychiatric symptoms need evidence-based treatment.Diversity in Aging-Related Neuroimaging Research
https://practicalneurology.com/diseases-diagnoses/imaging-testing/diversity-in-aging-related-neuroimaging-research/31761/There is a truly critical need to eliminate underrepresentation in aging-related neuroimaging research.Are Anti-amyloid Therapies Still Worth Being Developed as Treatments for Alzheimer's Disease?
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/are-anti-amyloid-therapies-still-worth-being-developed-as-treatments-for-alzheimers-disease/30832/Despite limited pharmaceutical success thus far, amyloid peptides may yet prove useful in the treatment of Alzheimer's and delay disease progression.Stiff-Person Syndrome
https://practicalneurology.com/diseases-diagnoses/movement-disorders/stiff-person-syndrome/31707/Treatment consists of immunomodulatory therapies and symptom management.